Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder

• Published in: International Urogynecology Journal Vol. 33; no. 3; pp. 703 - 709
• Main Authors: Eckhardt, Sarah E., Takashima, Yoko, Handler, Stephanie J., Tenggardjaja, Christopher, Yazdany, Tajnoos
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.03.2022; Springer Nature B.V
• Subjects: Administration, Intravesical; Adolescent; Anti-Bacterial Agents - therapeutic use; Antibiotic Prophylaxis; Antibiotics; Bladder; Botulinum toxin; Botulinum Toxins, Type A; Disease prevention; Female; Gynecology; Humans; Medicine; Medicine & Public Health; Original Article; Retrospective Studies; Urinary Bladder, Overactive - complications; Urinary Bladder, Overactive - drug therapy; Urinary retention; Urinary tract diseases; Urinary tract infections; Urinary Tract Infections - drug therapy; Urinary Tract Infections - etiology; Urinary Tract Infections - prevention & control; Urogenital system; Urology; Antibiotic prophylaxis; Urinary tract infections; Overactive bladder; Onabotulinumtoxin A
• ISSN: 0937-3462; 1433-3023
• DOI: 10.1007/s00192-021-04691-4

Introduction and hypothesis Guidelines vary on antibiotic prophylaxis for onabotulinumtoxinA (Botox) treatment for overactive bladder (OAB). Our primary objective was to determine whether any prophylactic regimen is more effective in preventing urinary tract infection (UTI) after Botox. The secondary objective was to identify prophylactic practice patterns among female pelvic medicine and reconstructive surgery (FPMRS) providers of different training backgrounds as well as general urologists. Methods This was a secondary analysis of a retrospective cohort study on urinary retention after Botox injection in women with and without diabetes mellitus and OAB. Women > 18 years old who underwent Botox injection for OAB between January 2013 and September 2018 were included. Exclusion criteria were history of urinary retention and neuromuscular bladder dysfunction. Results A total of 565 patients were included. Two hundred eighty (49.6%) were treated by OB-GYN FPMRS, 209 (37.0%) by urology FPMRS and 76 (13.5%) by general urologists. The majority (92.9%) received antibiotic prophylaxis: 44.4% received intravenous (IV) only, 8.9% received oral (PO) only, and 39.7% received combination IV and PO prophylaxis. Urology FPMRS used antibiotic prophylaxis less frequently ( p  = 0.003). Within 3 months, 171 patients developed UTI (30.4%). There was no difference in post-procedural UTI for any antibiotic regimen compared to no prophylaxis. No route of antibiotic administration was superior at preventing UTI. Conclusions In this cohort, no route of antibiotic administration was more effective in the prevention of UTI. Antibiotic prophylaxis did not lower the rate of post-procedural UTI compared to no antibiotics.